Johnson & Johnson Net Income 2006-2018 | JNJ

Johnson & Johnson annual/quarterly net income history and growth rate from 2006 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Johnson & Johnson net income for the quarter ending September 30, 2018 was $3.934B, a 4.52% increase year-over-year.
  • Johnson & Johnson net income for the twelve months ending September 30, 2018 was $1.542B, a 90.26% decline year-over-year.
  • Johnson & Johnson annual net income for 2017 was $1.3B, a 92.14% decline from 2016.
  • Johnson & Johnson annual net income for 2016 was $16.54B, a 7.34% increase from 2015.
  • Johnson & Johnson annual net income for 2015 was $15.409B, a 5.6% decline from 2014.
Johnson & Johnson Annual Net Income
(Millions of US $)
2017 $1,300
2016 $16,540
2015 $15,409
2014 $16,323
2013 $13,831
2012 $10,853
2011 $9,672
2010 $13,334
2009 $12,266
2008 $12,949
2007 $10,576
2006 $11,053
2005 $10,060
Johnson & Johnson Quarterly Net Income
(Millions of US $)
Q3 2018 $3,934
Q2 2018 $3,954
Q1 2018 $4,367
Q4 2017 $-10,713
Q3 2017 $3,764
Q2 2017 $3,827
Q1 2017 $4,422
Q4 2016 $3,814
Q3 2016 $4,272
Q2 2016 $3,997
Q1 2016 $4,457
Q4 2015 $3,215
Q3 2015 $3,358
Q2 2015 $4,516
Q1 2015 $4,320
Q4 2014 $2,521
Q3 2014 $4,749
Q2 2014 $4,326
Q1 2014 $4,727
Q4 2013 $3,519
Q3 2013 $2,982
Q2 2013 $3,833
Q1 2013 $3,497
Q4 2012 $2,567
Q3 2012 $2,968
Q2 2012 $1,408
Q1 2012 $3,910
Q4 2011 $218
Q3 2011 $3,202
Q2 2011 $2,776
Q1 2011 $3,476
Q4 2010 $1,942
Q3 2010 $3,417
Q2 2010 $3,449
Q1 2010 $4,526
Q4 2009 $2,206
Q3 2009 $3,345
Q2 2009 $3,208
Q1 2009 $3,507
Q4 2008 $2,714
Q3 2008 $3,310
Q2 2008 $3,327
Q1 2008 $3,598
Q4 2007 $2,374
Q3 2007 $2,548
Q2 2007 $3,081
Q1 2007 $2,573
Q4 2006 $2,168
Q3 2006 $2,760
Q2 2006 $2,820
Q1 2006 $3,305
Q4 2005 $2,095
Q3 2005 $2,538
Q2 2005 $2,588
Q1 2005 $2,839
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $389.718B $76.450B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $264.307B 14.90
Merck (MRK) United States $208.739B 18.09
Novartis AG (NVS) Switzerland $200.739B 17.21
AbbVie (ABBV) United States $131.784B 11.70
Eli Lilly (LLY) United States $120.858B 21.25
Novo Nordisk (NVO) Denmark $112.280B 18.23
Sanofi (SNY) France $110.782B 13.72
AstraZeneca (AZN) United Kingdom $97.289B 12.08
GlaxoSmithKline (GSK) United Kingdom $93.444B 12.56
Bristol-Myers Squibb (BMY) United States $85.821B 14.13